13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001825034
Total reported value
$439.8M
$439.8M
11 檔
165.2%
In Q4 2024, Euclidean Capital LLC's U.S. equity holdings reached a combined market value of $439.8M, distributed across 11 disclosed stock positions.
In Q4 2024, Euclidean Capital LLC adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 1 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 71.30% | — | -25.49% | |
| 2 | INDA | Ishares Msci India ETF | ETF-Other | 17.33% | -0.26% | — | |
| 3 | VEU | Vanguard Ftse All-world Ex-u | ETF-Other | 7.90% | -0.33% | +99.65% | |
| 4 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.08% | -0.76% | — | |
| 5 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 1.01% | -0.17% | — | |
| 6 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 0.54% | -0.03% | — | |
| 7 | ALEC | Alector Inc | Stock-Other | 0.34% | -0.12% | — | |
| 8 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.20% | -0.01% | — | |
| 9 | SRZN | Surrozen Inc | Stock-Other | 0.17% | -0.13% | — | |
| 10 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.14% | — | — | |
| 11 | SRZNW | Surrozen Inc-cw25 | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VEU | Vanguard Ftse All-world Ex-u | +4.4% | +99.65% | Add |
| 2 | INDA | Ishares Msci India ETF | +1.7% | — | Unchanged |
| 3 | PMVP | Pmv Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 4 | SRZN | Surrozen Inc | +0.1% | — | Unchanged |
| 5 | SRZNW | Surrozen Inc-cw25 | — | — | Unchanged |
| 6 | ✓ | Rapt Therapeutics Inc | 0% | — | Unchanged |
| 7 | TNYA | Tenaya Therapeutics Inc | 0% | — | Unchanged |
| 8 | ORIC | Oric Pharmaceuticals Inc | 0% | — | Unchanged |
| 9 | ALEC | Alector Inc | -0.3% | — | Unchanged |
| 10 | ✓ | -0.4% | EXIT | Sold out | |
| 11 | FHTX | Foghorn Therapeutics Inc | -0.6% | — | Unchanged |
| 12 | SPY | Ss Spdr S&p 500 ETF Trust-us | -4.8% | -25.49% | Trim |
According to official SEC Form 13F filings, Euclidean Capital LLC reported a total U.S. public equity portfolio value of $439.8M across 11 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SPY, INDA, VEU) accounted for 165.2% of total reported equity market value during Q4 2024.
Top Position Liquidated / Trimmed
前期市值: $3.6M
During Q4 2024, Euclidean Capital LLC's top holdings by market value included SPY (71.3%)、INDA (17.3%)、VEU (7.9%). The largest single position, SPY, represented 71.3% of total portfolio value.
In Q4 2024, Euclidean Capital LLC made 3 total portfolio adjustments, initiating 0 new buys, adding to 1 positions, trimming 1 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.